FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.

 

Brand: BCM

 

Signaling Pathways: Chromatin/Epigenetic

 

Solubility: Soluble in DMSO.

 

Isomeric SMILES: C[C@@H]1CN(C[C@@H](O1)C)C2=CC=CC(=N2)C3=CSC(=N3)NC(=O)[C@H](COC)NC(=O)C4=CN(C=C4)S(=O)(=O)C  

 

InChIKey: JBLQNFBXKOAIHG-FCEWJHQRSA-N  

 

InChI: InChI=1S/C24H30N6O6S2/c1-15-10-29(11-16(2)36-15)21-7-5-6-18(25-21)20-14-37-24(27-20)28-23(32)19(13-35-3)26-22(31)17-8-9-30(12-17)38(4,33)34/h5-9,12,14-16,19H,10-11,13H2,1-4H3,(H,26,31)(H,27,28,32)/t15-,16+,19-/m0/s1

 

Attribute
[Chem Name]	N-[(2S)-1-[[4-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl]-1,3-thiazol-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]-1-methylsulfonylpyrrole-3-carboxamide
[Synonym]	FHD-286; FHD 286; FHD286
[CAS No.]	2671128-05-3
[Formula]	C24H30N6O6S2
[Molecular]	562.66
[Form]	Solid
[Storage]	Sealed in dry. Stored at -20°C

Goods Tag